MAP2K1 and melanoma: As RAF inhibitors have been found to relieve the ERK1/2- dependent feedback inhibition of MAPK signaling, inhibition of MEK1/2 along with B-RAF is considered a promising strategy in the treatment of B-RAF -mutated melanoma and MEK inhibition has proved to be beneficial for NRAS-mutated melanoma (30–32).